Clinical Trial Update: NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab plus ipilimumab for metastatic hypermutated HER2-negative breast cancer; the study is active but not recruiting, with trial r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-09-27